NCCN Guideline Boosts Bladder Cancer Gene Therapy, Widening Patient Access

PARSIPPANY, NJ – March 19, 2026 – A pivotal update to the nation's leading cancer treatment playbook is set to expand options for a challenging group of bladder cancer patients. Ferring Pharmaceuticals’ gene therapy, ADSTILADRIN® (nadofaragene firadenovec-vncg), has received an upgraded Category 2A recommendation from the National Comprehensive Cancer Network® (NCCN®) for a specific subset of patients with non-muscle invasive bladder cancer (NMIBC).

The new recommendation, published in the 2026 NCCN Clinical Practice Guidelines, applies to patients with Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC who have papillary tumors but not the high-grade flat tumor known as carcinoma in situ (CIS). This move is particularly significant because while ADSTILADRIN is FDA-approved for other forms of BCG-unresponsive NMIBC, this specific use is not. The NCCN’s endorsement signals a strong expert consensus, potentially reshaping clinical practice and opening new doors for patients with limited alternatives.

Beyond the FDA: The Power of NCCN Guidelines

In the intricate world of oncology, the NCCN Guidelines often serve as the de facto standard of care, wielding influence that extends beyond the boundaries of FDA-approved labels. The organization, a non-profit alliance of leading cancer centers, develops its recommendations through panels of multidisciplinary experts. A Category 2A recommendation, like the one just granted to ADSTILADRIN, signifies uniform NCCN consensus that the treatment is appropriate, based on lower-level evidence that nonetheless points to clinical benefit.

This distinction is far from academic; it has profound real-world consequences for physicians, payers, and patients. For physicians, prescribing a drug for a non-FDA-approved use, or “off-label,” can be a gray area. However, an NCCN recommendation provides a powerful clinical justification, mitigating liability concerns and giving doctors confidence to use a therapy they believe will benefit their patient. It effectively codifies a standard of care where an FDA label does not yet exist.

Perhaps most critically, the NCCN’s endorsement directly impacts insurance coverage. Major health insurers, including UnitedHealthcare and Cigna, explicitly reference the NCCN Compendium in their coverage policies. A Category 2A recommendation is typically sufficient for these payers to deem a treatment medically necessary, ensuring that patients can access the therapy without facing insurmountable out-of-pocket costs. This update essentially unlocks a reimbursement pathway for ADSTILADRIN in this new patient population, a crucial step in translating a clinical recommendation into tangible patient access.

A New Lifeline for Patients with Limited Options

For patients diagnosed with high-risk NMIBC, the journey often begins with intravesical BCG, a type of immunotherapy that has been the standard of care for decades. While effective for many, a significant portion of patients—up to 50%—will eventually stop responding or see their cancer recur. For this “BCG-unresponsive” population, the prognosis becomes more serious, and the treatment options narrow dramatically.

Historically, the next step has often been radical cystectomy—the complete surgical removal of the bladder. This is a life-altering procedure with significant impacts on quality of life, and one that many patients, particularly the elderly or those with comorbidities, are unwilling or unable to undergo. This has created a vast unmet need for effective, bladder-sparing therapies.

ADSTILADRIN enters this space as a pioneering gene therapy. Administered directly into the bladder via a catheter once every three months, it uses a harmless, non-replicating adenovirus to deliver the gene for interferon alfa-2b. This approach turns the patient's own bladder wall cells into “interferon microfactories,” producing a naturally occurring protein that the body uses to fight cancer. The therapy offers a novel mechanism of action and a convenient dosing schedule that reduces the treatment burden on patients.

Long-term data from the therapy’s Phase 3 clinical trial underscores its durability. A five-year follow-up analysis showed that for the overall study population, the overall survival rate was 80%, and nearly half of the patients remained cystectomy-free at the 60-month mark. For the specific cohort of patients with papillary tumors (Ta/T1), two-thirds avoided bladder removal surgery after five years, demonstrating the therapy’s potential to provide a lasting, bladder-preserving outcome.

Navigating a Crowded and Evolving Treatment Landscape

The treatment landscape for BCG-unresponsive NMIBC has become increasingly dynamic in recent years. ADSTILADRIN is not the only advanced therapy vying to fill the treatment gap. It competes with Merck’s immunotherapy powerhouse, Keytruda® (pembrolizumab), which was approved in 2020. More recently, in April 2024, ImmunityBio’s Anktiva® (nogapendekin alfa inbakicept-pmln) gained FDA approval for use in combination with BCG.

Interestingly, Anktiva also recently received a similar NCCN Category 2A recommendation for papillary-only disease, suggesting a broader trend of expert panels recognizing the value of novel intravesical therapies for this specific patient group. The pipeline remains active as well, with other innovative treatments like the non-viral gene therapy Detalimogene voraplasmid and the oncolytic immunotherapy Cretostimogene grenadenorepvec advancing through late-stage trials.

Within this competitive field, ADSTILADRIN’s unique gene therapy mechanism and its robust long-term data on bladder preservation serve as key differentiators. The NCCN guideline update further solidifies its position, providing a clear endorsement for its use in a patient population with few good choices.

A Strategic Win for Ferring Pharmaceuticals

For Ferring Pharmaceuticals, a privately held biopharmaceutical company, the NCCN update is a significant commercial and strategic victory. Since launching ADSTILADRIN commercially in 2024, the company has focused on ensuring broad patient access, a goal now substantially advanced by this influential recommendation. Securing an NCCN endorsement for a non-FDA-approved indication is a shrewd strategy that expands the therapy’s addressable market and reinforces its value proposition to both clinicians and payers.

This clinical win is further bolstered by a solid financial foundation. Ferring successfully established an Average Sales Price (ASP) and secured a reimbursement pathway with the Centers for Medicare & Medicaid Services (CMS) as of April 2024, ensuring a stable payment structure for covered claims. The combination of expert clinical consensus from the NCCN and a clear reimbursement mechanism creates a powerful synergy that drives adoption.

The successful development and strategic positioning of ADSTILADRIN signal Ferring’s deep commitment to the uro-oncology space and its emergence as a leader in novel bladder cancer therapies. As the market for BCG-unresponsive NMIBC treatments continues to grow, this latest guideline update ensures that ADSTILADRIN will be a central part of the conversation, offering a much-needed option for patients striving to fight their cancer while preserving their quality of life.